BPC-157: Systemic Healing Peptide — Mechanisms, Routes & Protocols
BPC-157 is a pentadecapeptide derived from human gastric juice that heals tendons, ligaments, muscles, and the GI tract through multiple complementary pathways. Mechanisms, all administration routes, and dosage protocols by injury type.
Evidence strength
Level 4
Case series / Animal studies
Peer-reviewed refs
7
Reading time
15 min
Key Takeaways
- BPC-157 accelerates healing of tendons, ligaments, muscles, and GI mucosa through at least 4 distinct molecular pathways operating simultaneously.
- Oral dosing is effective for gastrointestinal issues — the peptide resists gastric degradation and acts locally on the gut mucosa.
- Injectable BPC-157 near the injury site produces the strongest local effect, but systemic subcutaneous dosing also works for multiple or inaccessible injuries.
- The Wolverine Stack (BPC-157 + TB-500) covers both local and systemic repair simultaneously — consistently reported as more effective than either peptide alone.
- BPC-157 promotes angiogenesis — it is contraindicated in active cancer or cancer history. Not FDA or EMA approved for human use.
- All published mechanistic data is from animal studies. Human evidence consists of case series and clinical observations. Oxford Level 4.
What Is BPC-157?
Body Protection Compound 157 (BPC-157) is a synthetic pentadecapeptide — 15 amino acids long — derived from a protective protein found in human gastric juice. It was isolated and characterised by Professor Predrag Sikiric at the University of Zagreb, where the majority of the published research originates.
The "157" in its name refers to its position within the parent gastric protein. While the natural parent protein serves a protective function in the stomach, BPC-157 itself demonstrates tissue repair effects far beyond the GI tract — tendons, ligaments, muscles, bone, and neural tissue all respond to it in animal models.
What distinguishes BPC-157 from most research peptides is the volume of published data. The Sikiric group has published extensively on it across three decades, from gastrointestinal cytoprotection to vascular and musculoskeletal healing. While this is still predominantly animal research, the depth of mechanistic characterisation is unusual in the peptide space.
[1]Mechanism of Action: Four Pathways
BPC-157 does not work through a single receptor or pathway. Its healing effects emerge from simultaneous activity across at least four distinct molecular mechanisms.
1. VEGF Upregulation and Angiogenesis
The most studied mechanism. BPC-157 increases expression of Vascular Endothelial Growth Factor (VEGF) at injury sites, driving the formation of new capillaries into damaged tissue. This angiogenic response is essential for healing: without adequate blood supply, even otherwise viable repair cells cannot receive oxygen and nutrients.
Crucially, BPC-157 behaves differently from the standard angiogenic growth factors (EGF, FGF, VEGF): it is given alone, without a carrier, and in rat studies it was the only agent consistently effective across acute and chronic injury models of the oesophagus, stomach, duodenum and lower gastrointestinal tract.
[2]2. Growth Hormone Receptor Sensitisation
BPC-157 upregulates growth hormone receptors in healing tissue. This is a fundamentally different mechanism from simply raising GH levels — it makes target tissues more responsive to whatever GH is already circulating.
This explains the well-documented synergy with Ipamorelin: Ipamorelin increases circulating GH levels; BPC-157 increases the sensitivity of injured tissue to that GH. The result is amplified GH-mediated collagen synthesis and tissue repair at exactly the sites where it is needed.
3. Nitric Oxide Synthesis Modulation
BPC-157 modulates nitric oxide (NO) pathways in a context-dependent manner. In injured tissue with compromised blood flow, it upregulates NO to improve vasodilation and perfusion. In tissue with excessive inflammation, it normalises NO to reduce inflammatory damage.
This bidirectional NO modulation is characteristic of a true tissue protector rather than a simple stimulant. In rats, BPC-157 had no effect on normal blood pressure but blunted the rise caused by the NO-synthase inhibitor L-NAME and prevented the fall caused by L-arginine. That NO-system activity is why patients on antihypertensives should monitor blood pressure during BPC-157 use.
[4]4. FAK-Paxillin Pathway Activation
The FAK (Focal Adhesion Kinase) — paxillin signalling complex governs cell migration and adhesion. BPC-157 activates this pathway, accelerating the directed migration of fibroblasts toward the injury site. Fibroblasts are the primary cells responsible for synthesising collagen and extracellular matrix — the structural material of tendons, ligaments, and connective tissue.
In practical terms: BPC-157 does not just send a healing signal, it actively directs the cells that do the healing to arrive faster and in greater numbers.
Applications by Tissue Type
Tendon and Ligament Injuries
The application with the strongest animal model evidence. In the seminal 2003 study, rats with transected Achilles tendons treated with BPC-157 showed greater load to failure and elasticity, higher Achilles functional index scores, more fibroblast and collagen formation, and smaller tendon defects than controls.
[5]What this means clinically: Tendons and ligaments are notoriously slow to heal due to their poor blood supply. BPC-157's angiogenic effect directly addresses this limitation — it creates the vascular infrastructure that these tissues normally lack, enabling repair processes to proceed at a rate closer to well-vascularised muscle.
Protocol for tendon/ligament injuries:
- 500mcg subcutaneous, injected as close to the injury site as practical
- Twice daily (morning + evening)
- 4-6 week loading phase, then assess
- For chronic injuries (>3 months): consider extending to 8 weeks
Muscle Injuries
A 2006 study demonstrated consistently improved healing of complete quadriceps muscle transection in rats treated with BPC-157 versus controls over 72 days. Treated rats showed greater load to failure, better walking recovery, muscle fibres bridging the cut segments, and less muscle atrophy.
[6]For muscle injuries, the injection does not need to be immediately adjacent to the injury — subcutaneous injection anywhere near the affected region (or systemically) produces meaningful results.
Bone and Tendon-to-Bone Interface
The tendon-to-bone interface (enthesis) is one of the most biomechanically complex tissue junctions in the body and one of the most difficult to repair. In a rat model where the Achilles tendon was cut from the heel bone, BPC-157 improved tendon-to-bone healing functionally, biomechanically and histologically, and counteracted the healing delay caused by corticosteroids — suggesting possible application in post-surgical recovery and avulsion injuries, though human data are lacking.
[7]Gastrointestinal Repair
The application that is unique to BPC-157 among peptides. Because it was derived from gastric juice and is naturally resistant to proteolytic degradation in the stomach, BPC-157 retains biological activity when taken orally.
Conditions with supporting animal data:
- Inflammatory bowel disease (IBD)
- Gastric and duodenal ulcers
- Leaky gut syndrome (intestinal hyperpermeability)
- NSAID-induced GI damage
- Short bowel syndrome
- Oesophageal and pyloric sphincter dysfunction
Oral protocol for GI issues:
- 250-500mcg in water, on empty stomach
- Twice daily (morning and evening)
- 4-6 weeks minimum for mucosal conditions
Administration Routes: A Practical Comparison
| Route | Best For | Onset | Bioavailability |
|---|---|---|---|
| Subcutaneous (near injury) | Tendon, ligament, joint injuries | 30-60 min | High local concentration |
| Subcutaneous (any site) | Systemic, muscle, multiple injuries | 30-60 min | Good systemic distribution |
| Intramuscular | Deep tissue injuries | 20-40 min | Rapid systemic |
| Oral (capsule/solution) | GI tract conditions | 45-90 min | Active in GI lumen |
| Intranasal | Experimental — TBI, neurological | 15-30 min | Limited data |
Dosage Reference by Use Case
| Condition | Dose | Frequency | Duration |
|---|---|---|---|
| Acute tendon/ligament tear | 500mcg | 2x daily | 4-6 weeks |
| Chronic tendinopathy | 250-500mcg | 2x daily | 6-8 weeks |
| Muscle strain (grade 2-3) | 250-500mcg | 1-2x daily | 3-4 weeks |
| GI repair (ulcer, IBD) | 250-500mcg oral | 2x daily | 4-6 weeks |
| Post-surgical recovery | 500mcg | 2x daily | 4-8 weeks |
| Preventative (athletes) | 250mcg | 1x daily | Cycle with training |
All doses are in micrograms (mcg), not milligrams. Note: 0.5mg = 500mcg.
The Wolverine Stack: BPC-157 + TB-500
The most consistently reported observation in the BPC-157 community is that combining it with TB-500 (Thymosin Beta-4) produces outcomes that neither peptide achieves alone. The mechanistic rationale is straightforward:
BPC-157 works locally: Its primary effects are concentrated at and near the injection site. It creates the angiogenic and molecular repair environment for a specific tissue region.
TB-500 works systemically: Its primary mechanism (actin regulation and cell migration via Tβ4) operates throughout the body, mobilising repair cells from bone marrow and directing them systemically.
The combination means: TB-500 recruits repair cells from across the body and delivers them systemically; BPC-157 creates the local molecular environment that directs and amplifies what those cells do when they arrive at the injury site.
Standard Wolverine Stack protocol:
- BPC-157: 500mcg subcutaneous, near injury site, morning + evening
- TB-500: 5mg subcutaneous, any site, once daily (morning)
- Duration: 4-6 week loading phase
- Maintenance: BPC-157 250mcg/day + TB-500 5mg/week
See the full TB-500 (Thymosin Beta-4) profile and the Wolverine Stack Protocol for complete guidance.
Reconstitution and Storage
Reconstitution: BPC-157 is supplied as a lyophilised (freeze-dried) white powder. Reconstitute with bacteriostatic water only — not sterile water, which lacks the preservative and will not keep the reconstituted peptide stable.
Standard reconstitution: 1ml bacteriostatic water per 5mg vial gives a concentration of 5mg/ml (5000mcg/ml). For a 500mcg dose, draw 0.1ml (10 units on an insulin syringe).
Storage:
- Lyophilised powder: freezer at -20°C, indefinite stability
- Reconstituted: refrigerator at +4°C, use within 4 weeks
- Never freeze reconstituted peptide
Injection technique: Use an insulin syringe (29G or 31G, 0.5ml or 1ml). Pinch a fold of skin near the injury site. Insert at 45-90 degrees. Inject slowly. Rotate sites to prevent local tissue changes.
Sourcing: Why COA Matters
BPC-157 quality varies enormously between suppliers. The key verification is a third-party Certificate of Analysis (COA) from a reputable analytical laboratory (Janoshik, Zylorion, Peptide Pros) confirming:
- Purity by HPLC: Should be ≥98%
- Sequence verification by mass spectrometry: Confirms correct amino acid sequence
- Sterility testing: Absence of bacterial contamination
- Heavy metals: Absence of contamination
Do not use any supplier unwilling to provide current, third-party COA documentation for each batch. Given that this compound is injected, this is a non-negotiable safety requirement.
Regulatory Status and Important Disclaimer
BPC-157 is a research chemical. It is not approved by the FDA or EMA for human therapeutic use. In 2022, the FDA issued guidance restricting BPC-157 use in compounding pharmacies, effectively removing it from the US pharmaceutical compounding pathway.
All information in this article is provided for educational and informational purposes only. It does not constitute medical advice. Consult a qualified healthcare professional before using any research peptide.
Related Substances
Scientific References
- [1]Sikiric P, Rucman R, Turkovic B, et al.. Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing — Current Pharmaceutical Design (2018)Oxford 4PMID 29879879
- [2]Seiwerth S, Rucman R, Turkovic B, et al.. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing — Current Pharmaceutical Design (2018)Oxford 4PMID 29998800
- [3]Vitaic S, Stupnisek M, Drmic D, et al.. Nonsteroidal anti-inflammatory drugs-induced failure of lower esophageal and pyloric sphincter and counteraction of sphincters failure with stable gatric pentadecapeptide BPC 157 in rats — Journal of Physiology and Pharmacology (2017)Oxford 4PMID 28614776
- [4]Sikirić P, Seiwerth S, Grabarević Z, et al.. The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure — European Journal of Pharmacology (1997)Oxford 4PMID 9298922
- [5]Staresinic M, Sebecic B, Patrlj L, et al.. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth — Journal of Orthopaedic Research (2003)Oxford 4PMID 14554208
- [6]Staresinic M, Petrovic I, Novinscak T, et al.. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157 — Journal of Orthopaedic Research (2006)Oxford 4PMID 16609979
- [7]Krivic A, Anic T, Seiwerth S, et al.. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation — Journal of Orthopaedic Research (2006)Oxford 4PMID 16583442
Follow us on Google Search
Add BiohackingHub as a preferred source to see more of our research in Google results.
Related protocols
Partner with BiohackingHub
Editorial placements, sponsorships, and product features for evidence-minded brands.